Immunology and Microbiology
Vaccination Policy
100%
Immunotherapy
100%
interferon
100%
Philadelphia 1 Chromosome
100%
Cancer Immunotherapy
100%
Programmed Death 1 Ligand 1
100%
Immunocompetent Cell
50%
Immune Response
50%
Cytokine
50%
Immune System
50%
T Cell
50%
Tumor Antigen
50%
Blocking Antibody
50%
Cancer Vaccine
50%
Hematopoietic Stem Cell
50%
Immune Dysregulation
50%
Keyphrases
Myeloproliferative Neoplasms
100%
Chronic Myeloproliferative Neoplasms
100%
Philadelphia Chromosome-negative
100%
Cancer Immune Therapy
100%
Interferon-α (IFN-α)
25%
Therapeutic Vaccination
25%
Programmed Death-ligand 1 (PD-L1)
25%
Arginase
25%
Therapeutic Potential
12%
Immunosuppressive Cytokines
12%
Immune System
12%
New Treatment Options
12%
T Cells
12%
Chronic Inflammation
12%
Bone Marrow
12%
Tumor Antigen
12%
Regulatory Mechanism
12%
Janus Kinase 2 (JAK2)
12%
Neoplastic Disease
12%
Immune Regulation
12%
Therapeutic Vaccine
12%
Inhibitory Pathways
12%
Cancer Immunotherapy
12%
Hematopoietic Stem Cells
12%
Immune Dysregulation
12%
Adoptive Cell Therapy
12%
Anticancer Immunotherapy
12%
Preclinical Investigation
12%
Regulatory Immune Cells
12%
Anticancer Immune Response
12%
Driver mutations
12%
Checkpoint Blocking Antibody
12%
Immune Checkpoint Blocking
12%
Medicine and Dentistry
Malignant Neoplasm
100%
Philadelphia 1 Chromosome
100%
Immunotherapy
100%
Myeloproliferative Neoplasm
100%
Interferon
20%
Cancer Immunotherapy
20%
Arginase
20%
Programmed Death 1 Ligand 1
20%
Cytokine
10%
Neoplasm
10%
Chronic Inflammation
10%
T Cell
10%
Immune System
10%
Immune Response
10%
Immunocompetent Cell
10%
Tumor Antigen
10%
Cancer Vaccine
10%
Hematopoietic Stem Cell
10%
Cell Therapy
10%
Janus Kinase
10%
Immune Dysregulation
10%
Blocking Antibody
10%